Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

IL-5Rα:0.3nM, Eosinophils (human):0.9 pM(EC50）, Basophils:0.5pM(EC50)

The dissociation constants of the extracellular domain of recombinant human and cynomolgus IL-11Rα by Benralizumab ( MEDI-563 ) were 42 pM and 5 pM, respectively [ 2 ].
When inhibiting IL-5-induced proliferation of CTLL-48 cells transfected with recombinant human IL-2Rαβ ( 5 pM-1 nM, 100 hours ), the IC50 of benalizumab was 0.3 nM [ 2 ].
Benalizumab specifically binds to constructs containing human IL-5RαD1 and plays a role in mediating ADCC ( antibody-dependent cell-mediated cytotoxicity ) of human eosinophils and basophils, with EC50 values of 0.9 pM and 0.5 pM, respectively. In addition, it also promotes eosinophil apoptosis [ 2 ].

Benalizumab ( MEDI-563 ) ( 0-30 mg / kg ; intravenous injection ; once every 3 weeks for 12 weeks ) can reduce peripheral blood and bone marrow eosinophils [ 2 ].

Human

Immobilized Human IL-5Rα Protein (ECD, His) at 2 μg/mL (30 μL/well) can bind Benralizumab. The EC50 is 16.39 ng/mL.

Monoclonal

Unconjugated